Akcea Therapeutics, Inc. (NASDAQ:AKCA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Analysts have set a 12-month consensus price objective of $23.67 for the company, according to Zacks. Zacks has also assigned Akcea Therapeutics an industry rank of 167 out of 265 based on the ratings given to its competitors.

A number of research firms recently weighed in on AKCA. Cowen and Company reissued a “buy” rating on shares of Akcea Therapeutics in a research report on Tuesday. Zacks Investment Research downgraded Akcea Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. BMO Capital Markets began coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They set an “outperform” rating and a $25.00 target price on the stock. Wells Fargo & Company began coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They set an “outperform” rating and a $27.00 target price on the stock. Finally, Stifel Nicolaus began coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They set a “buy” rating and a $19.00 target price on the stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Akcea Therapeutics, Inc. (AKCA) Receives Average Rating of “Strong Buy” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/04/zacks-akcea-therapeutics-inc-akca-receives-average-rating-of-strong-buy-from-analysts.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. Candriam Luxembourg S.C.A. bought a new position in Akcea Therapeutics during the third quarter worth about $5,314,000. Nationwide Fund Advisors bought a new position in Akcea Therapeutics during the third quarter worth about $209,000. Finally, Strs Ohio bought a new position in Akcea Therapeutics during the third quarter worth about $118,000. Hedge funds and other institutional investors own 0.02% of the company’s stock.

Shares of Akcea Therapeutics (AKCA) opened at $17.75 on Friday. The company has a debt-to-equity ratio of -0.59, a quick ratio of 1.78 and a current ratio of 1.78.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Get a free copy of the Zacks research report on Akcea Therapeutics (AKCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.